Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

Ron Kurtz, Chief Executive Officer and President of RxSight, said, “Given RxSight’s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket after the company slashed its full-year guidance and announced lower-than-expected preliminary revenue ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the s ALISO VIEJO, Calif., April 02 ...

The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL™/LAL+ ®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...